A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6272-6283

  Johnson, Todd J ^a   Clark, Meredith R ^b   Albright, Theodore H ^a   Nebeker, Joel S ^a   Tuitupou, Anthony L ^a   Clark, Justin T ^a   Fabian, Judit ^a   McCabe, R Tyler ^a   Chandra, Neelima ^b   Doncel, Gustavo F ^b   Friend, David R ^b   Kiser, Patrick F ^a  

^a Department of Electrical and Computer Engineering   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; POLYURETHAN; TENOFOVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; EQUIPMENT DESIGN; FEMALE; HIV INFECTIONS; IRRITANTS; ORGANOPHOSPHONATES; POLYURETHANES; SHEEP; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84869234019     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01431-12     Document Type: Article

References (62)

1. Abdool Karim Q, et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
2. Barnhart KT, et al. 2005. Distribution of a 3.5-mL (1.0%) C31G vaginal gel using magnetic resonance imaging. Contraception 71:357-361.
3. Barnhart KT, Timbers K, Pretorius ES, Lin K, Shaunik A. 2005. In vivo assessment of NuvaRing placement. Contraception 72:196-199.
4. Baum MM, et al. 2012. An intravaginal ring for the simultaneous delivery of multiple drugs. J. Pharm. Sci. 101:2833-2843.
5. Bounds W, Szarewski A, Lowe D, Guillebaud J. 1993. Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring. Eur. J. Obstet. Gynecol. Reprod. Biol. 48:123-125.
6. Clark JT, et al. 2012. Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. J. Control. Release 163:240-248.
7. Clark MR, Friend DR. 17 April 2012, posting date. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits. AIDS Res. Hum. Retroviruses doi:10.1089/aid.2011.0328.
8. Duncan GW. 1970. Medicated devices and methods. US patent 3,545,439.
9. Eckstein P, Jackson MCN, Millman N, Sobrero AJ. 1969. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J. Reprod. Fertil. 20:85-93.
10. Entrican G, Wheelhouse NM. 2006. Immunity in the female sheep reproductive tract. Vet. Res. 37:295-309.
11. Evans G, Maxwell WMC, Salamon S. 1987. Salamon's artificial insemination of sheep and goats. Butterworth-Heinemann, Oxford, England.
12. Fetherston SM, Malcolm RK, Woolfson AD. 2010. Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides. Ther. Deliv. 1:785-802.
13. Frandson RD, Wilke WL, Fails AD. 2009. Anatomy and physiology of farm animals. John Wiley & Sons, Hoboken, NJ.
14. Fraser IS, et al. 2000. Vaginal epithelial surface appearances in women using vaginal rings for contraception. Contraception 61:131-138.
15. Friend DR. 2012. Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission. Expert Opin. Drug Deliv. 9:417-427.
16. Friend DR. 2011. Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections. Drug Deliv. Transl. Res. 1:185-193.
17. Garg S, et al. 2001. Compendium of pharmaceutical excipients for vaginal formulations. Pharm. Technol. Drug Deliv. 1:14-18, 20-24.
18. Gunawardana M, et al. 2011. Microbial biofilms on the surface of intravaginal rings worn in non-human primates. J. Med. Microbiol. 60:828-837.
19. Hladik F, Hope TJ. 2009. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep. 6:20-28.
20. International Conference on Harmonisation. 2009. Guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. European Agency for the Evaluation of Medicinal Products topic M3(R2). ICH, Geneva, Switzerland.
21. Johnson TJ, Gupta KM, Fabian J, Albright TH, Kiser PF. 2010. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur. J. Pharm. Sci. 39:203-212.
22. Johnson TJ, et al. 2012. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob. Agents Chemother. 56:1291-1299.
23. Karim SS, Kashuba AD, Werner L, Karim QA. 2011. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378:279-281.
24. Kashuba A, et al. 2010. Do systemic and genital tract tenofovir concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trial?, abstr TUSS0503. Abstr. XVIII Int. AIDS Conf., Vienna, Austria.
25. Kiser PF, Johnson TJ, Clark JT. 2012. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev. 14:62-77.
26. Klasse PJ, Shattock R, Moore JP. 2008. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu. Rev. Med. 59:455-471.
27. Koetsawang S, et al. 1990. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. Contraception 41:125-141.
28. Lamba NMK, Woodhouse KA, Cooper SL, Lelah MD. 1998. Polyurethanes in biomedical applications. CRC Press, Boca Raton, FL.
29. Lamont RF, et al. 2011. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 118:533-549.
30. Malcolm RK, et al. 2012. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob. Agents Chemother. 56:2251-2258.
31. Manes J, et al. 2010. Changes in the aerobic vaginal flora after treatment with different intravaginal devices in ewes. Small Rumin. Res. 94:201-204.
32. Mayer KH, et al. 2006. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 20:543-551.
33. Mehta S, et al. 2012. Vaginal distribution and retention of a multiparticulate drug delivery system, assessed by gamma scintigraphy and magnetic resonance imaging. Int. J. Pharm. 426:44-53.
34. Mishell DR, Jr, Talas M, Parlow AF, Moyer DL. 1970. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Am. J. Obstet. Gynecol. 107:100-107.
35. Moss JA, et al. 2012. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. AIDS 26:707-710.
36. Moss JA, et al. 2012. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob. Agents Chemother. 56:875-882.
37. Nuttall J, Wan CM, Mowat V, Ross V, Romano J. 2010. Preclinical toxicological evaluation of the dapivirine vaginal ring in the sheep, abstr 153. Abstr. Microbicides 2010, Pittsburgh, PA.
38. Promadej-Lanier N, et al. 2009. Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates. J. Med. Primatol. 38:263-271.
39. Richardson JL, Illum L. 1992. Routes of delivery: case studies. The vaginal route of peptide and protein drug delivery. Adv. Drug Deliv. Rev. 8:341-366.
40. Romano J, et al. 2009. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retroviruses 25:483-488.
41. Roumen FJME, Dieben TOM. 1999. Clinical acceptability of an ethylenevinyl-acetate nonmedicated vaginal ring. Contraception 59:59-62.
42. Saltzman WM. 2001. Drug delivery: engineering principles for drug therapy. Oxford University Press, New York, NY.
43. Sarkar NN. 2005. The combined contraceptive vaginal device (NuvaRing): a comprehensive review. Eur. J. Contracept. Reprod. Health Care 10:73-78.
44. Saxena BB, et al. 2009. Sustained release of microbicides by newly engineered vaginal rings. AIDS 23:917-922.
45. Schwartz JL, et al. 2011. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 6:e25974. doi:10.1371/journal.pone.0025974.
46. Shattock RJ, Warren M, McCormack S, Hankins CA. 2011. Turning the tide against HIV. Science 333:42-43.
47. Sivin I, et al. 1997. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD. Contraception 55:225-232.
48. Smith DJ, et al. 2008. An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: behaviors and attitudes that might influence uptake within a high-risk population. J. Womens Health 17:1025-1034.
49. Sparks MH, et al. 2009. Drug release characteristics of dapivirine and tenofovir from vaginal rings consisting of ethylene vinyl acetate, silicone or polyurethane polymers: options for HIV prevention, abstr T2363. Abstr. AAPS Annu. Meet. Expo., Los Angeles, CA.
50. Timmer CJ, Mulders TMT. 2000. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin. Pharmacokinet. 39:233-242.
51. UNAIDS. 2010. Report on the global AIDS epidemic. Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland. http://www.unaids.org/ globalreport/global-report.htm.
52. Van Damme L, et al. 2008. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359:463-472.
53. Van Damme L, et al. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-977.
54. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. 2012. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26:F13-F19.
55. van Laarhoven JA, Kruft MA, Vromans H. 2002. In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. Int. J. Pharm. 232:163-173.
56. Vargas G, et al. 2012. Quantitative assessment of microbicide-induced injury in the ovine vaginal epithelium using confocal microendoscopy. BMC Infect. Dis. 12:48.
57. Vincent KL, et al. 2009. High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex. Transm. Dis. 36:312-318.
58. Walensky RP, et al. 2012. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin. Infect. Dis. 54: 1504-1513.
59. Weisberg E, et al. 2000. A randomized comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of a ring. Contraception 62:83-89.
60. Wieder DR, Pattimakiel L. 2010. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing). Int. J. Womens Health 2:401-409.
61. Williams BG, Abdool Karim SS, Karim QA, Gouws E. 2011. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J. Acquir. Immune Defic. Syndr. 58:207-210.
62. Woolfson AD, Malcolm RK, Gallagher R. 2000. Drug delivery by the intravaginal route. Crit. Rev. Ther. Drug Carrier Syst. 17:509-555.